30 results
8-K
EX-2.1
ODYY
Odyssey Health, Inc.
5 Oct 23
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
6:30am
and lifespan in pediatric disorders where de-myelination and cell death is widespread in the cortex and cerebellum regions of the brain and the study of ONP-002 … of ONP-001 seeking to improve function and lifespan in pediatric disorders where de-myelination and cell death is widespread in the cortex
8-K
EX-10.1
ODYY
Odyssey Health, Inc.
4 Nov 22
Odyssey Health Inc. Strengthens Commitment to Odyssey NeuroPharma Through Expansion of Executive Team
4:16pm
60 days after the date of the Executive’s death.
(b) All payments to be made upon a termination of employment under this Agreement may only be made
8-K
EX-10.2
n1x4v7g
4 Nov 22
Odyssey Health Inc. Strengthens Commitment to Odyssey NeuroPharma Through Expansion of Executive Team
4:16pm
DEF 14A
9v75bm7toj77qk5kkoz
6 Aug 21
Definitive proxy
4:02pm
PRER14A
l2nt85fjoxl4g7wn4l
28 May 21
Preliminary revised proxy
5:09pm
PRE 14A
acs420qm4cb5x4f2b
7 May 21
Preliminary proxy
5:27pm
S-3
zhpq3
17 Mar 21
Shelf registration
4:30pm
8-K
EX-10.1
3dt6ppwg
26 Jan 21
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-10.2
kfg2c
26 Jan 21
Entry into a Material Definitive Agreement
4:55pm
8-K
fmh0lfoppr3s
26 Jan 21
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-10.5
n8a1m
8 Jan 21
Entry into a Material Definitive Agreement
5:21pm